More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/RDEA119 [923032-37-5]

RDEA119 [923032-37-5]

Research Use Only
R1217
LKT Laboratories
Estimated Purity≥98%
Product group Chemicals
€ 284,00
5 mg
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    LKT Laboratories
  • Product Name
    RDEA119 [923032-37-5]
  • Delivery Days Customer
    7
  • Certification
    Research Use Only
  • Estimated Purity
    ≥98%
  • Format
    DMSO 100 mg/mL (174.72 mM); Ethanol 100 mg/mL (174.72 mM); Water Insoluble
  • Scientific Description
    MEK1/2 inhibitor.; Refametinib, BAY 869766; N-[3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]-cyclopropanesulfonamide; BAY 869766; BAY 8697661
  • Storage Instruction
    -20°C
  • UNSPSC
    12352200

References

  • Weekes CD, Von Hoff DD, Adjei AA, et al. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43. PMID: 23434733. Liu D, Xing J, Trink B, et al. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer. 2010 Dec 15;127(12):2965-73. PMID: 21351275. Iverson C, Larson G, Lai C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009 Sep 1;69(17):6839-47. PMID: 19706763.